Arbutus Presents HBV Drug Combination Studies at AASLD

Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary Action
Capsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA Synthesis
Second Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program

VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in two oral presentations and one poster presentation at the 2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held on November 11-15, 2016, in Boston. These presentations feature two Arbutus pipeline programs and highlight the potential of Arbutus’ combination development strategy with robust preclinical data showing complementary action when combining Arbutus assets with approved HBV therapies.

“We are very excited to present, for the first time, results from the

... read more at: http://www.econotimes.com/Arbutus-Presents-HBV-Drug-Combination-Studies-at-AASLD-400852

by